Please use this identifier to cite or link to this item: https://doi.org/10.1055/s-0034-1377044
DC FieldValue
dc.titleLatent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications
dc.contributor.authorLeow M.K.
dc.contributor.authorDalan R.
dc.contributor.authorChee C.B.
dc.contributor.authorEarnest A.
dc.contributor.authorChew D.E.
dc.contributor.authorTan A.W.
dc.contributor.authorKon W.Y.
dc.contributor.authorJong M.
dc.contributor.authorBarkham T.
dc.contributor.authorWang Y.T.
dc.date.accessioned2020-10-20T01:24:38Z
dc.date.available2020-10-20T01:24:38Z
dc.date.issued2014
dc.identifier.citationLeow M.K., Dalan R., Chee C.B., Earnest A., Chew D.E., Tan A.W., Kon W.Y., Jong M., Barkham T., Wang Y.T. (2014). Latent tuberculosis in patients with diabetes mellitus: prevalence, progression and public health implications. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 122 (9) : 528 - 532. ScholarBank@NUS Repository. https://doi.org/10.1055/s-0034-1377044
dc.identifier.issn14393646
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/177741
dc.description.abstractBACKGROUND: Diabetes mellitus (DM) confers a higher risk for tuberculosis (TB). Yet, TB screening and chemoprophylaxis for latent TB infection (LTBI) in DM remains controversial. We conducted a cross-sectional study to elucidate LTBI prevalence and longitudinal follow-up to ascertain LTBI to active TB progression rate in DM.METHODS: 220 DM patients without previous TB from the outpatient diabetes clinic of the hospital were enrolled. T-Spot TB, tuberculin-skin-test (TST) and chest radiography (CXR) were performed. LTBI was defined by negative CXR with reactive T-Spot TB. Progression to active TB was confirmed by cross-checking against the TB registry.RESULTS: The prevalence of LTBI was 28.2% (62/220) by reactive T-Spot. None progressed to active TB from 2007-2013. Multivariate analysis revealed that any co-morbidity (p=0.016) was positively associated while metformin (p=0.008) was negatively associated with LTBI.CONCLUSIONS: Over a quarter of DM patients harbor LTBI. While the lack of demonstrable progression to active TB within the follow-up time frame up to this point does not unequivocally support a routine TB screening policy or anti-TB chemoprophylaxis for LTBI in a diabetic population for now, this preliminary evidence needs re-evaluation with longer follow-up of this enrolled cohort over the next decade. J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart New York.
dc.sourceScopus
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.contributor.departmentMICROBIOLOGY AND IMMUNOLOGY
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1055/s-0034-1377044
dc.description.sourcetitleExperimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
dc.description.volume122
dc.description.issue9
dc.description.page528 - 532
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
There are no files associated with this item.

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.